NASDAQ · JUNS
Jupiter Neurosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for JUNS: Nov 13, 2026
Jupiter Neurosciences, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-5.26.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Quiver Quantitative- RTTNews · Oct 6, 11:42 AM EDTJupiter Neurosciences Starts Phase 2a Parkinson's Trial Of JOTROL(RTTNews) – Jupiter Neurosciences Inc. (JUNS) said the first patient has been dosed in its Phase 2a RESET clinical trial evaluating JOTROL in patients with Parkinson's disease.
- RTTNews · Aug 31, 10:21 AM EDTJupiter Neurosciences Shares Plunge After Nasdaq Delisting Notice(RTTNews) – Shares of Jupiter Neurosciences, Inc. (JUNS), a clinical-stage company, plunged more than 25% after the company disclosed that Nasdaq had notified it of a staff determination to delist its common stock from the Nasdaq Capital Market.
- RTTNews · Aug 22, 7:37 AM EDTJupiter Posts Wider Loss In Q2, Announces Pricing Of $2 Mln Direct Offering(RTTNews) – Jupiter Neurosciences, Inc. (JUNS), a clinical-stage biopharmaceutical company, reported a second-quarter loss compared to a year-ago quarter. The company also announced the pricing of a registered direct offering.
- RTTNews · Aug 5, 10:58 AM EDTJupiter Neurosciences Announces 1-for-75 Reverse Stock Split Effective August 6; Stock Down(RTTNews) – Jupiter Neurosciences, Inc. (JUNS), a clinical-stage biopharmaceutical company focused on therapies for neurological and neurodegenerative disorders, has approved a 1-for-75 reverse stock split of its common stock.
- RTTNews · Jul 21, 9:33 AM EDTJupiter Neurosciences Signs $100 Million U.S. Rights Deal For ALA-002; Stock Up(RTTNews) – Jupiter Neurosciences, Inc. (JUNS) announced it has signed a definitive license agreement with PharmAla Biotech Holdings Inc. (MDXXF) for perpetual exclusive U.S. rights to ALA-002, a patented non-racemic MDMA formulation designated as a Novel Chemical Entity (NCE) by
- RTTNews · May 21, 6:09 AM EDTJupiter Announces Pricing Of $2 Mln Direct Offering; Shares Drop By 35%(RTTNews) – Jupiter Neurosciences Inc. (JUNS), a clinical-stage biopharmaceutical company, on Wednesday announced entry into a security purchase agreement.
- RTTNews · May 20, 11:13 AM EDTJupiter Neurosciences Surges On Securing $100 Mln Term Sheet For ALA-002's US Licensing Rights(RTTNews) – PharmAla Biotech Holdings Inc., a biotechnology company, announced that it has entered into a term sheet under which PharmAla would grant Jupiter Neurosciences, Inc. (JUNS) exclusive, perpetual United States licensing rights to ALA-002, a PharmAla's patented, non-race
- RTTNews · Jan 28, 4:40 AM ESTJupiter Neurosciences To Showcase Lead Program JOTROL At The DealFlow Discovery Conference(RTTNews) – Jupiter Neurosciences, Inc. (JUNS), a clinical-stage pharmaceutical company, is scheduled to participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.
- Quiver Quantitative · Jul 23, 8:14 AM EDTJupiter Neurosciences Highlights Breakthrough JOTROL™ Resveratrol Platform with Enhanced Bioavailability and Therapeutic PotentialJupiter Neurosciences highlights JOTROL™, a resveratrol platform improving bioavailability and reducing GI side effects, advancing toward Parkinson's trials.
- Quiver Quantitative · Jul 10, 4:13 PM EDTJupiter Neurosciences, Inc. Regains Nasdaq Compliance as Stock Price Shows Positive MomentumJupiter Neurosciences confirms Nasdaq compliance after stock price stabilization above $1.00 for 13 days, ending prior delisting concerns.
- Quiver Quantitative · Jun 30, 3:20 PM EDTJupiter Neurosciences Launches Nugevia™ PWR: A Science-Driven Cellular Energy Supplement for LongevityJupiter Neurosciences introduces Nugevia™ PWR, a mitochondrial health supplement supporting energy and recovery, launching Fall 2025.
- Quiver Quantitative · Jun 23, 8:13 AM EDTJupiter Neurosciences Appoints Annika Sörenstam as First Brand Ambassador for Nugevia™ Longevity Supplement LineAnnika Sörenstam becomes brand ambassador for Jupiter Neurosciences' Nugevia™ longevity supplements, emphasizing science-backed formulations for health and performance.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Jupiter Neurosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.